Last May, a 13-year-old girl was the world’s first patient to receive base-edited T cells for her incurable T cell leukemia. Since then, two more children have been treated and results were published in The New England Journal of Medicine on Wednesday.  

Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials. As these programs mature, 2023 could be a pivotal year for companies in the space.